Funding for this research was provided by:
National Health and Medical Research Council
Received: 23 September 2020
Accepted: 21 December 2020
First Online: 10 January 2021
Ethics approval and consent to participate
: The Melbourne Health Human Ethics committee approved study procedures (2015.012), and all participants provided written informed consent.
: Not applicable.
: TOB reports grants from Eisai Pharmaceuticals, other from UCB Pharma, grants from Biogen, other from ES Pharmaceuticals, other from Supernus Pharmaceuticals. ZC has received consultancy fees and/or research grants from Arvelle Therapeutics and UCB Pharma.